Correction: Evaluating the pentapharmacological potency of otamixaban against lung cancer CDK2, transferase, oxidoreductase and signalling proteins.

Baeissa, Hanadi M; Bakhsh, Tahani; Shakoori, Afnan Mohammed; Sindi, Ghadir; Zaki, Randa Mohammed; Kamal, Mohammad Azhar; Alsufyani, Hadeel A; Habib, Alaa Hamed et al. · PLoS One · 2026

Where this comes from

Record sourced from PubMed, PMID 41801824.
Also identified by DOI 10.1371/journal.pone.0344592 and PMC identifier 12970878.
No licence information is recorded for this record.
Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.

Abstract

[This corrects the article DOI: 10.1371/journal.pone.0334013.].

Read the full text

View on PubMed · Publisher (DOI)